Journal
BRITISH JOURNAL OF CANCER
Volume 128, Issue 8, Pages 1541-1547Publisher
SPRINGERNATURE
DOI: 10.1038/s41416-023-02177-2
Keywords
-
Categories
Ask authors/readers for more resources
A study shows that the use of SGLT2 inhibitors is associated with improved overall survival in non-small cell lung cancer patients with pre-existing diabetes, even after considering potential confounders. This study provides evidence for the potential role of SGLT2 inhibitors in the treatment of non-small cell lung cancer.
BackgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of antidiabetic drugs with demonstrated renal and cardiovascular disease benefit. This study evaluates the role of SGLT2 inhibitors on the survival of non-small cell lung cancer (NSCLC) patients.MethodsWe used National Surveillance, Epidemiology and End Results (SEER)-Medicare linked data. Twenty four thousand nine hundred fifteen NSCLC patients newly diagnosed between 2014 and 2017 with pre-exiting diabetes and aged 66 years or older were included and followed to the end of 2019. Information on SGLT2 inhibitors use was extracted from the Medicare Part D file.ResultsSGLT2 inhibitor use was associated with significantly reduced mortality risk after adjusting for potential confounders (HR = 0.68, 95% CI = 0.60-0.77) with stronger association for longer duration of use (HR = 0.54, 85% CI = 0.44-0.68). Further, we found that SGLT2 inhibitor use was associated with a significant reduced risk of mortality regardless of patients' demographic, tumour characteristics and cancer treatments.ConclusionOur large SEER-Medicare linked data study indicates that SGLT2 inhibitors use was associated with improved overall survival of NSCLC patients with pre-existing diabetes. Further studies are needed to confirm our findings and elucidate the possible mechanisms behind the association.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available